Atreca’s $125M round paves way for first immunotherapy into clinic

Atreca Inc. (Redwood City, Calif.) raised $125 million in a series C round led by an undisclosed U.S.-based healthcare fund, clearing the way for the company to move its first cancer immunotherapy into the clinic.

Fellow existing investors Wellington Capital and Cormorant Asset Management, as well as new investors Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management also participated...